

SUPPLEMENTAL TABLE 1: Observed Values of Outcome Measures During Continuation Treatment


| Primary Outcomes | Paroxetine + PE | | | Placebo + PE | | |
|---|-----------------|------|------|----------------|------|------|
| | N ^a | Mean | SD | N ^a | Mean | SD |
| Clinician-Administered PTSD Scale | | | | | | |
| Week 10 | 13 | 21.5 | 19.9 | 13 | 35.6 | 31.3 |
| Week 14 | 11 | 31.7 | 23.2 | 11 | 27.7 | 19.0 |
| Week 18 | 11 | 30.4 | 24.6 | 10 | 27.0 | 23.9 |
| Week 22 | 10 | 30.4 | 30.7 | 11 | 27.9 | 21.1 |
| | | | | | | |
| | No./N | % | | No/N | % | |
| Remission | | | | | | |
| Week 10 | 8/13 | 61.5 | | 3/13 | 23.1 | |
| Week 14 | 3/9 | 33.3 | | 2/10 | 20.0 | |
| Week 18 | 4/9 | 42.9 | | 3/9 | 33.3 | |
| Week 22 | 5/9 | 55.6 | | 4/10 | 40.0 | |
| | | | | | | |
| Secondary Outcomes | Paroxetine + PE | | | Placebo + PE | | |
| | No./N | % | | No/N | % | |
| Response | | | | | | |
| Week 10 | 12/13 | 92.3 | | 7/13 | 53.8 | |
| Week 14 | 6/9 | 66.7 | | 8/10 | 80.0 | |
| Week 18 | 7/9 | 77.8 | | 5/9 | 55.6 | |
| Week 22 | 6/9 | 66.7 | | 7/10 | 70.0 | |
| | | | | | | |
| | N ^a | Mean | SD | N ^a | Mean | SD |
| Hamilton Rating Scale for Depression | | | | | | |
| Week 10 | 13 | 7.7 | 3.7 | 14 | 11.4 | 6.7 |
| Week 14 | 11 | 6.9 | 5.0 | 10 | 8.1 | 5.8 |
| Week 18 | 10 | 7.8 | 6.4 | 11 | 8.8 | 6.9 |
| Week 22 | 10 | 8.2 | 7.1 | 11 | 7.7 | 7.7 |
| | | | | | | |
| Quality of Life Enjoyment and Satisfaction Questionnaire^b | | | | | | |
| Week 10 | 9 | 67.9 | 12.7 | 10 | 54.8 | 22.3 |
| Week 22 | 9 | 57.4 | 18.1 | 8 | 54.5 | 28.1 |

Abbreviations: PE, Prolonged Exposure Therapy

^aSample sizes vary by time point and measure due to attrition and missing data.

^bHigher scores represent better quality of life.

SUPPLEMENTAL FIGURE 1: Clinician-Administered PTSD Scale (CAPS) Scores During Continuation Treatment, By Group with Standard Deviation Bars



SUPPLEMENTAL FIGURE 2: Remission Rates During Continuation Treatment, By Group

